Management of progressive brain metastases in patients (pts) with relapsed germ-cell tumor (GCT) treated with salvage high-dose chemotherapy (HDCT).

被引：0
|
作者：
King, Jennifer
Abonour, Rafat
Hassoun, Rebecca
Althouse, Sandra K.
Salous, Tareq
Hanna, Nasser H.
Einhorn, Lawrence H.
Adra, Nabil
机构：
[1] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN USA
[2] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA
[3] Indiana Univ, Melvin & Simon Comprehens Canc Ctr, Indianapolis, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5036
引用
收藏
页数：1
相关论文
共 50 条
  • [1] High-dose chemotherapy (HDCT) plus peripheral-blood stem-cell transplant (PBSCT) for patients (pts) with relapsed germ-cell tumors (GCT) and active brain metastases (mets).
    Kalra, Maitri
    Adra, Nabil
    Mckay, John
    Abonour, Rafat
    Hanna, Nasser H.
    Einhorn, Lawrence H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Salvage high-dose chemotherapy (HDCT) for relapsed primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT).
    Taza, Fadi
    Abonour, Rafat
    Althouse, Sandra K.
    Ashkar, Ryan
    Abu Zaid, Mohammad Issam
    Hanna, Nasser H.
    Kessler, Kenneth A.
    Adra, Nabil
    Einhorn, Lawrence H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors
    Lorch, A.
    Neubauer, A.
    Hackenthal, M.
    Dieing, A.
    Hartmann, J. T.
    Rick, O.
    Bokemeyer, C.
    Beyer, J.
    ANNALS OF ONCOLOGY, 2010, 21 (04) : 820 - 825
  • [4] Prognostic factors for high-dose chemotherapy (HDCT) as salvage treatment in germ cell tumors (GCT)
    Beyer, J
    Kramar, A
    Mandanas, R
    Linkesch, W
    Greinix, A
    Droz, JP
    Pico, JL
    Diehl, A
    Bokemeyer, C
    Schmoll, HJ
    Nichols, CR
    Einhorn, LH
    Siegert, W
    BONE MARROW TRANSPLANTATION, 1998, 22 : S10 - S10
  • [5] Has toxicity in young patients with Germ Cell Tumor (GCT) treated with High-Dose Chemotherapy (HDCT) any impact on weight?
    Giannotti, F
    Civinelli, MC
    Martelli, S
    Amati, P
    Peccenini, R
    Zambianchi, H
    Papiani, G
    De Giorgi, L
    Cavallaro, M
    Rosti, G
    Marangolo, M
    BONE MARROW TRANSPLANTATION, 2001, 27 : S389 - S389
  • [6] Outcome in 41 patients with late relapse germ cell tumors (GCT) treated with high-dose chemotherapy (HDCT)
    Lorch, A.
    Rick, O.
    Hartmann, J. T.
    Metzner, B.
    Glasmacher, A.
    Berdel, W.
    Schirren, R.
    Bokemeyer, C.
    Beyer, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Serum tumor marker (STM) decline rates during high-dose chemotherapy (HDCT) to predict outcome for germ cell tumor (GCT) patients (pts).
    Feldman, Darren Richard
    Voss, Martin Henner
    Jia, Xiaoyu
    Van Alstine, Lindsay Joy
    Patil, Sujata
    Fischer, Patricia
    Sheinfeld, Joel
    Bosl, George J.
    Motzer, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] High-dose chemotherapy (HDCT) as second salvage treatment in patients with multiple relapsed or refractory germ cell tumors
    Beyer, J.
    Hackenthal, M.
    Lorch, A.
    Neubauer, A.
    Dieing, A.
    Rick, O.
    Hartmann, J. T.
    Bokemeyer, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Risk factors for renal failure (RF) during high-dose chemotherapy (HDCT) and outcomes for patients (pts) with relapsed germ-cell tumors (rGCT).
    Zhang, Kevin Juan
    Hanna, Nasser H.
    Abu Zaid, Mohammad Issam
    Abonour, Rafat
    Albany, Costantine
    Einhorn, Lawrence H.
    Adra, Nabil
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Single versus sequential high-dose chemotherapy (HOCT) in patients with relapsed or refractory germ-cell tumors (GCT).
    Lorch, A.
    Rick, O.
    Hartmann, J. T.
    Kollmannsberger, C.
    Metzner, B.
    Schmidt-Wolf, I.
    Berdel, W. E.
    Schirren, R.
    Beyer, J.
    Bokemeyer, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 219S - 219S
12345